Skip to main content
Premium Trial:

Request an Annual Quote

Biocept KRAS Liquid Biopsy Test

Biocept has launched a new blood-based KRAS mutation test to help physicians identify patients who might benefit from currently available targeted therapies. According to the company the high sensitivity of its technology could also allow the test to be used for monitoring patients' responses to treatment and the progression of their disease during the course of therapy.

The quantitative Target Selector KRAS assay joins Biocept's existing portfolio of liquid biopsy tests for melanoma, breast, lung and gastric cancer biomarkers. The firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.